Article
<i>ABCB1</i>GENE POLYMORPHISMS ARE ASSOCIATED WITH CLINICAL RESPONSE TO NABIXIMOLS IN PATIENTS WITH MULTIPLE SCLEROSIS-RELATED SPASTICITY
2025-06-20
Abstract excerpt
<h4>Background</h4> Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system causing severe symptoms, including spasticity-related pain. Nabiximols (NBX), a drug combining Tetrahydrocannabinol and Cannabidiol, is approved for MS-associated spasticity. Despite NBX efficacy, only 60-70% of patients respond to treatment. This study explores whether genetic polymorphisms in key genes involved in...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b5ae7b89-32da-54d8-97e3-84881668f205
- DOI
- 10.1101/2025.06.20.25329925
